Blue Matter Blog
November 27, 2023
Once an emerging biopharma company has committed to launching its first product and building the required commercial organization to support doing so, its leaders must begin to understand the magnitude of change associated with this decision. A biopharma company building its commercialization capabilities is quite different from a smaller R&D-focused organization, and adding new functions …
November 21, 2023
As we covered in the previous articles on this topic, Part 1 and Part 2, the line between medical devices and consumer wearables is increasingly blurring. Consumer wearables become more medicalized in their functionality, and medical devices become more appropriate for consumer applications. There are many underlying causes for this shift, including the cost reduction …
November 20, 2023
For any company, a new product launch is a big deal. For an emerging biopharma company, the decision to launch a first product is a really big deal that sets in motion organizational transformation and a wide range of launch readiness activities. A biopharma company launching its first product will have significant investments over the …
November 13, 2023
Targeted protein degradation (TPD) is an attractive concept that has been studied and refined over the past two decades. It leverages cells’ existing “infrastructure” to signal specifically targeted disease-causing proteins for degradation. This can be via: A “molecular glue” – directly engages the signalling moiety with the protein of interest (POI) A heterobifunctional molecule – …
November 6, 2023
Late last month, a couple of teams from Blue Matter attended the ESMO Congress in Madrid, both for project work and to stay abreast of the latest innovations in oncology. One of those teams prepared a summary of their key takeaways, which you can read here. However, ESMO is a large meeting, and it’s impossible …
November 2, 2023
The weather may have been rainy, but it didn’t dampen the enthusiasm of the more than 30,000 people who attended the 2023 ESMO Congress in Madrid, 20-24 October. Members of our team traveled to Madrid to see the latest innovations in oncology research and patient care. While there, we combed through the agenda to find—and …